|
Volumn 10, Issue SUPPL. 3, 2001, Pages 58-61
|
Breast cancer chemoprevention - Quo vadis?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANASTROZOLE;
ANTINEOPLASTIC AGENT;
AROMATASE INHIBITOR;
BIPHOSPHONATE IBANDRONATE;
GONADORELIN ANTAGONIST;
GOSERELIN;
ISOFLAVONE DERIVATIVE;
NOVOGEN;
PHYTOESTROGEN;
PLACEBO;
RALOXIFENE;
SELECTIVE ESTROGEN RECEPTOR MODULATOR;
TAMOXIFEN;
TIBOLONE;
UNCLASSIFIED DRUG;
ADULT;
AGED;
ARTICLE;
ASIA;
AUSTRALIA;
BONE DENSITY;
BONE MINERAL;
BREAST CANCER;
CANCER INCIDENCE;
CHEMOPROPHYLAXIS;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
ENDOMETRIUM CANCER;
FEMALE;
FOLLOW UP;
FRACTURE;
HUMAN;
HUMAN TISSUE;
MAMMOGRAPHY;
OSTEOPOROSIS;
PRIORITY JOURNAL;
PUBLICATION;
RANDOMIZED CONTROLLED TRIAL;
SIDE EFFECT;
SURVIVAL;
THROMBOEMBOLISM;
UNITED KINGDOM;
|
EID: 0034916453
PISSN: 09609776
EISSN: None
Source Type: Journal
DOI: 10.1054/brst.2000.0218 Document Type: Article |
Times cited : (3)
|
References (12)
|